Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Abstract Background Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone....

Full description

Bibliographic Details
Main Authors: Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama, Xavier Préville
Format: Article
Language:English
Published: BMJ Publishing Group 2017-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cancer vaccine
Viral vaccine
Tumor associated antigen
Lung cancer
T cell response
Online Access:http://link.springer.com/article/10.1186/s40425-017-0274-x

Internet

http://link.springer.com/article/10.1186/s40425-017-0274-x

Similar Items